Capitalising on HealthTech Regulation: Analysis of Thoma Bravo’s Acquisition of padoa

Nelson Advisors
10 minutes ago
9 min read

Strategic Transaction Overview

In a milestone transaction within the European healthcare technology sector, software private equity firm Thoma Bravo announced and finalised its strategic growth investment in padoa, acquiring a majority stake in the European leader in occupational health, safety, and prevention software. The transaction, executed through the €1.8 billion Thoma Bravo Europe Fund, represents a notable expansion of the firm’s dedicated buyout strategy across core European software markets.

The deal structure encompasses significant reinvestment and continued equity participation from padoa's co-founders and executive management team, alongside its long-standing institutional sponsors, Five Arrows, the alternative assets arm of Rothschild & Co and Kamet Ventures.

Founded in 2016 within the venture studio Kamet Ventures, padoa has established a digital health platform dedicated to occupational health centres (Services de Prévention et de Santé au Travail - SPST), healthcare practitioners, enterprise employers and individual employees in France. By providing an integrated digital ecosystem that streamlines medical monitoring, risk prevention, administrative workflows, and statutory compliance, padoa currently supports over two million workers and more than 200,000 enterprises across its core jurisdiction.

The recapitalisation by Thoma Bravo represents an institutional inflection point in padoa's capital structure and commercial roadmap. Having previously completed an €80 million funding round led by Five Arrows Growth Capital in February 2022, which brought total pre-buyout capital raised to approximately €105 million ($119 million) padoa’s ownership transition from growth-stage venture building to private equity control provides the operational scale and M&A deployment capacity required to pursue cross-border expansion, with an immediate strategic focus on the DACH region.

Source: https://www.thomabravo.com/press-releases/thoma-bravo-completes-acquisition-of-padoa

Transaction Parameter	Details and Specifications
Target Company	padoa (Headquarters: Paris, France)
Acquiring Entity	Thoma Bravo (via Thoma Bravo Europe Fund)
Transaction Structure	Majority Equity Strategic Growth Investment with Reinvestment
Rollover Shareholders	Co-Founders/Management, Five Arrows (Rothschild & Co), Kamet Ventures
Target Sector	Healthcare SaaS / Occupational Health & Safety Software
Key Financial Advisor	William Blair (Financial Advisor to Thoma Bravo)
Key Legal Counsel	Goodwin Procter (To Thoma Bravo); McDermott Will & Schulte (To Sellers)
Target Enterprise Footprint	2,000,000+ Monitored Employees; 200,000+ Enterprises; 18+ Major SPST Centers

Deal Architecture and Governance Framework

The architecture of the transaction balances leadership continuity with institutional scaling capacity. Thoma Bravo assumes majority control of the business, while padoa’s co-founder, President, and Chief Executive Officer, Cédric Mathorel, alongside the existing executive team, retain a substantial equity stake to guide operational execution.

Equity alignment is further reinforced through reinvestment from Five Arrows—investing via its corporate private equity platform and Kamet Ventures, led by Chairman Stéphane Guinet, who originally incubated the business.

The cross-border advisory network involved in the deal underscores the scale and regulatory oversight of the transaction. William Blair acted as the exclusive financial advisor to Thoma Bravo. Legal counsel to Thoma Bravo was delivered by Goodwin Procter's Paris equity team, led by partners Maxence Bloch and Simon Servan-Schreiber, alongside partners Marie-Laure Bruneel on tax matters and Adrien Paturaud on corporate financing. The selling shareholders, including Five Arrows, Kamet Ventures, and the founding partners, were advised by McDermott Will & Schulte's Paris team, led by partners Grégoire Andrieux and Marie-Muriel Barthelet.

Under this ownership structure, the capital platform combines Thoma Bravo Europe Fund as the controlling sponsor, flanked by Five Arrows, Kamet Ventures, and founding executives maintaining minority governance seats and operational alignment. This arrangement preserves padoa's institutional memory and regulatory standing in France while embedding Thoma Bravo’s software operating playbook. Irina Hemmers, Partner and Head of European Operations at Thoma Bravo, alongside Principal David Tse, led the investment from the firm's London office.

The deal validates padoa's core unit economics and recurring SaaS revenue metrics, enabling the business to apply Thoma Bravo's functional toolkits across software sales execution, pricing strategy, R&D efficiency, and programmatic add-on acquisitions.

Platform Architecture and Regulatory Moat

The padoa technology architecture is designed as a multi-sided software platform that digitises occupational health workflows previously reliant on legacy infrastructure and paper processes. The platform integrates four core constituencies within a unified digital environment. For occupational health centres (SPST), padoa delivers administrative and medical management software that optimises appointment scheduling, staff capacity allocation, billing, and clinical record management.

Healthcare practitioners, including occupational physicians, nurses, and multidisciplinary specialists, utilise specialised clinical modules to track individual health trajectories, perform biometric evaluations and log preventative interventions. Enterprise employers gain access to central management dashboards to monitor workforce health indicators, ensure statutory medical check-up compliance, and co-author mandatory workplace risk evaluations. Concurrently, individual employees interact with personal portals to manage medical appointments, access health tracking profiles, and receive preventative educational resources.

Platform Capability / Compliance Module	Technical & Functional Description	Strategic Value / Market Impact
DUERP Numérique(Document Unique)	Digitized workplace risk assessment and prevention action planning framework	Ensures compliance with French mandatory risk assessment statutes
IRDP (Indicateur de Risque de Désinsertion)	Predictive risk assessment engine detecting job loss and medical incapacity risks early	Reached 51% coverage of examined workers across partner SPST centers in 2024
SPST Workflows & CRM	Integrated administrative, medical record, and billing software suite	Replaces legacy software; harmonizes cross-departmental workflows
Data Security & Privacy Infrastructure	Certified under HDS (Hébergeur de Données de Santé) and ISO 27001/27701	Establishes a technical and regulatory barrier to entry for non-compliant SaaS vendors

A driver of padoa’s commercial adoption in France is the statutory momentum generated by the Loi Santé au Travail(Law of August 2, 2021, implemented on March 31, 2022). This legislative framework modernised French occupational health requirements, reorienting service delivery from reactive medical surveillance toward continuous workplace risk prevention, multidisciplinary team coordination, and early intervention against professional desinsertion.

The legislation imposed strict operational mandates, including the digital recording and updating of the Document Unique d'Évaluation des Risques Professionnels (DUERP), alongside the integration of occupational health data into centralized national medical frameworks. padoa’s software architecture natively satisfies these regulatory mandates. Specialised platform capabilities, such as the Indicateur de Risque de Désinsertion Professionnelle (IRDP), which enables medical teams to identify workers at risk of health-related employment interruption, have become operational standards across major health institutions including GIMS, CIAMT, and Pôle Santé Travail.

In addition, padoa's strict compliance with French medical data hosting statutes (Hébergeur de Données de Santé - HDS) together with ISO 27001 and ISO 27701 information security certifications creates a defensible market position. In the European healthcare software sector, localised data sovereignty requirements and jurisdictional regulatory barriers create structural defensive moats, preventing generic global HR software platforms or enterprise resource planning (ERP) suites from easily encroaching on specialized occupational health workflows.

Strategic Growth Thesis: AI Integration and European Scale

Thoma Bravo’s value creation thesis centres on transitioning padoa from a French market leader into a consolidated, pan-European occupational health technology provider. Capital deployment across the investment cycle is structured around four strategic initiatives: deep artificial intelligence integration, international expansion into the DACH region, enterprise HR ecosystem extension, and programmatic M&A consolidation.

The deployment of artificial intelligence within padoa's software environment is designed to address the structural deficit of occupational physicians across European health systems. By automating routine clinical documentation, synthesizing longitudinal health records prior to patient check-ups, and deploying predictive risk analytics for workplace hazard detection, padoa reduces administrative workloads. This efficiency enables multidisciplinary medical staff to reallocate operational time toward proactive clinical care and workplace risk prevention.

Geographic scaling beyond France forms the second core driver of growth. The DACH region (Germany, Austria, and Switzerland) represents the primary focus for cross-border expansion. Germany’s statutory workplace health frameworks (Arbeitsschutzgesetz and Arbeitsicherheitsgesetz) closely align with French regulatory requirements, providing an organic total addressable market (TAM) expansion opportunity for compliance-oriented enterprise SaaS platforms.

Concurrently, padoa is broadening its target market from occupational health centers directly to enterprise and mid-market employers. Enhancing SME-focused applications, such as padoa’s digital "Single Document" risk assessment module, allows enterprise customers to embed occupational health metrics directly into corporate Environmental, Social, and Governance (ESG) reporting, workforce management systems, and workplace safety frameworks.

Finally, backed by Thoma Bravo’s capital base, padoa is positioned to execute a buy-and-build acquisition strategy. The platform intends to evaluate targeted add-on acquisitions of niche healthcare software vendors, regional point solutions, and local clinical software competitors across Germany, Benelux, and Southern Europe to accelerate international market penetration.

Industry Context: Thoma Bravo’s European Expansion Strategy

The padoa acquisition illustrates the active deployment of Thoma Bravo’s dedicated European software strategy. Having deployed more than €14 billion of equity across 17 European platform transactions over the past 15 years, the establishment of the firm’s London office in 2023 under Irina Hemmers served to accelerate regional deal execution.

The final close of the €1.8 billion Thoma Bravo Europe Fund provided a dedicated capital pool specifically structured to acquire middle-market European software platforms characterised by strong unit economics, high recurring revenue visibility and defensible localised market positioning.

Portfolio Asset	HQ Location	Primary Focus Area	Strategic Investment Angle
padoa	France	Occupational Health, Safety & Prevention SaaS	AI-driven workflow scaling and DACH regional expansion
LOGEX	Netherlands	Healthcare Analytics & Clinical Costing Software	Operational efficiency and clinical data optimization
EQS Group	Germany	Corporate Compliance & RegTech SaaS	€400m take-private focused on European compliance mandates
Hypergene	Sweden	Strategic Planning & Performance Management SaaS	Mid-market SaaS growth acceleration across Nordics
USU	Germany	Enterprise IT & Asset Management Software	Cloud transformation and operational modernization

European B2B software assets present distinct market dynamics that align with private equity value creation models. Historically operating with more disciplined venture capital funding than North American peers, European software providers have typically prioritized early profitability, efficient capital deployment, and sustainable unit economics over unconstrained market share acquisition.

In addition, macroeconomic and regulatory tailwinds continue to drive European software spending. Cloud migration across Western Europe remains an ongoing structural transition—with approximately 68% of enterprise workloads still running on-premise or in hybrid environments—while complex localized regulatory frameworks, including the EU AI Act and national healthcare laws, reward software vendors capable of embedding compliance directly into product workflows. These dynamics create defensible, cash-generative software assets suitable for buyout capitalization.

Corporate Evolution and Financing Timeline

padoa’s institutional progression reflects a disciplined scaling path from venture incubation to majority private equity ownership. Incubated in 2016 within Kamet Ventures, the company focused its early engineering efforts on developing compliant software architecture tailored to French occupational health regulations. By establishing early partnerships with major SPST centers, padoa validated its multi-sided platform model connecting medical centers, enterprise clients, and workers.

By February 2022, padoa secured an €80 million Series B funding round led by Five Arrows Growth Capital, with Kamet Ventures and the founding team retaining equity stakes. This capital injection funded R&D expansion, supported the recruitment of over 60 software engineers and healthcare specialists, and scaled the platform’s coverage to 18 major SPST centers monitoring over two million workers.

The completion of Thoma Bravo’s majority acquisition in 2026 marks padoa’s entry into institutional private equity ownership. With over $172 Billion in assets under management as of March 31, 2026, and a historic portfolio of approximately 590 technology companies representing $320 billion in aggregate enterprise value, Thoma Bravo provides the balance sheet capacity and operational infrastructure to transition padoa into a pan-European software leader.

While specific deal valuation multiples were not publicly disclosed, market context and previous financing benchmarks reflect the asset's scale. The reinvestment of capital by Five Arrows—managing €13 billion in corporate private equity—and Kamet Ventures underlines long-term institutional conviction in padoa’s recurring SaaS revenue trajectory and margin expansion potential. The continued participation of existing sponsors ensures padoa retains access to established institutional and healthcare networks as it executes cross-border growth.

Conclusion and Strategic Outlook

Thoma Bravo’s growth investment in padoa demonstrates the strategic acquisition of a specialised healthcare software provider positioned at the intersection of regulatory compliance, digital transformation, and enterprise risk management. By structuring a majority transaction alongside rollover participation from padoa’s founders, Five Arrows, and Kamet Ventures, Thoma Bravo secures an established platform benefiting from statutory market demand and recurring SaaS revenues.

The capital partnership transitions padoa from a domestic market leader in France into an expanding pan-European healthtech consolidator. As padoa deploys artificial intelligence capabilities to enhance clinical efficiency and expands its footprint into the DACH region, the transaction provides a clear model for scaling regulatory-driven B2B software assets across European markets.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics